二乙基-(3-溴-丙基)-胺 | 108553-02-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 二乙基-(3-溴-丙基)-胺
• 英文名称: diethyl-(3-bromo-propyl)-amine
• 英文别名: Diaethyl-(3-brom-propyl)-amin；1-Brom-3-diaethylamino-propan；Diaethyl-(γ-brom-propyl)-amin；3-diethylamino propyl bromide；3-bromo-N,N-diethylpropan-1-amine
• CAS: 108553-02-2
• 化学式: C₇H₁₆BrN
• 分子量: 194.115
• InChiKey: UPASYJUQYLIDMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  二乙基-(3-溴-丙基)-胺 生成 1,1-diethyl-azetidinium; bromide
  参考文献：
  名称：

  Quaternary Ammonium Salts from Bromopropyldialkylamines. IV. Formation of Four-Membered Rings

  摘要：

  DOI：

  10.1021/ja01318a059
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 作用下， 生成 二乙基-(3-溴-丙基)-胺
  参考文献：
  名称：

  Noda; Sakamoto; Ishii, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 366;dtsch.Ref.S.106

  摘要：

  DOI：

文献信息

• Imidazoisoquinoline-diones and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US04176184A1

  公开（公告）日：1979-11-27

  Compounds of the formula ##STR1## wherein R.sub.1 is lower alkyl; phenyl-lower alkyl; cycloalkyl of 3 to 6 carbon atoms; phenyl; mono- or di-substituted phenyl, where the substituents, which may be identical to or different from each other, are each halogen, hydroxyl, methoxy, methylmercapto, methylsulfinyl, methylsulfonyl or benzyloxy; and A is hydrogen or ##STR2## where R.sub.2 is hydrogen or lower alkyl; R.sub.3 is lower alkyl or dimethoxyphenyl-lower alkyl; or R.sub.2 and R.sub.3, together with each other and the nitrogen atom to which they are attached, are piperidino, morpholino or N'-lower alkyl-piperazino; and n is 2 or 3; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as cardiotonics, hypotensives, antithrombotics and antiarrhythmics.

  式为##STR1##的化合物，其中R.sub.1为较低的烷基；苯基-较低的烷基；3至6个碳原子的环烷基；苯基；单取代或双取代的苯基，取代基可以相同也可以不同，每个取代基都是卤素、羟基、甲氧基、甲硫氧基、甲砜基或苄氧基；A为氢或##STR2##，其中R.sub.2为氢或较低的烷基；R.sub.3为较低的烷基或二甲氧基苯基-较低的烷基；或R.sub.2和R.sub.3，连同它们彼此和它们附着的氮原子，为哌啶基、吗啉基或N'-较低的烷基-哌嗪基；n为2或3；以及其非毒性、药理学上可接受的酸盐。这些化合物及其盐可用作心力衰竭药、降压药、抗血栓药和抗心律失常药。
• Studies on 3-aminoindazoles. I. Synthesis of 1- or 3-(substituted 3-amino)indazoles.
  作者：HIROMU KAWAKUBO、KENTARO FUKUZAKI、TAKANORI SONE

  DOI：10.1248/cpb.35.2292

  日期：——

  Various 1-or 3- (substituted 3-amino) indazoles with anti-inflammatory effects were synthesized by means of three methods, as follows. 1) Reactions of 3-aminoindazole (1) with acrylamides (2a and 2b) gave amide derivatives (3a and 3b) having a carbamoylethylamino group at the 3-position of 3a and 3b. The amide derivatives (3a and 3b) were converted to thioamide derivatives (4a and 4b) by treatment with P2S5. Electrode reduction of 4a and 4b gave 3- (substituted 3-amino) indazoles (5a and 5b). 2) The reaction of 1 with aminoalkyl. halides (6c-r) gave 3- (substituted 3-amino) indazoles (5c-r) and 1- (substituted 3-amino) indazoles (7c-r) in a ratio of 3 : 1. 3) The reaction of 1 with phthalic anhydride (8) gave 3-phthalimidoindazole (9). Compound 9 was allowed to react with aminoalkyl halides (6o-r) to give 1-substituted derivatives (10s-z) of 9, Reactions of 10a-z with hydrazine hydrate gave 1- (substituted 3-amino) indazole derivatives (5s-z).

  通过以下三种方法合成了各种具有消炎作用的 1-或 3-（取代的 3-氨基）吲唑。1) 3-氨基吲唑（1）与丙烯酰胺（2a 和 2b）反应，得到酰胺衍生物（3a 和 3b），3a 和 3b 的 3 位上有氨基甲酰乙氨基。酰胺衍生物（3a 和 3b）经 P2S5 处理后转化为硫代酰胺衍生物（4a 和 4b）。电极还原 4a 和 4b，得到 3-（取代的 3-氨基）吲唑（5a 和 5b）。2) 1 与氨基烷基卤化物（6c-r）反应，得到 3-（取代的 3-氨基）吲唑（5c-r）和 1-（取代的 3-氨基）吲唑（7c-r），比例为 3 : 1。化合物 9 与氨基烷基卤化物 (6o-r) 反应，得到 9 的 1-取代衍生物 (10s-z)，10a-z 与水合肼反应，得到 1-（取代的 3-氨基）吲唑衍生物 (5s-z)。
• Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities
  作者：Sumalee Kamchonwongpaisan、Netnapa Charoensetakul、Choladda Srisuwannaket、Supannee Taweechai、Roonglawan Rattanajak、Jarunee Vanichtanankul、Danoo Vitsupakorn、Uthai Arwon、Chawanee Thongpanchang、Bongkoch Tarnchompoo、Tirayut Vilaivan、Yongyuth Yuthavong

  DOI：10.1016/j.ejmech.2020.112263

  日期：2020.6

  and shown to inhibit P. falciparum dihydrofolate reductase (PfDHFR) of the wild type or those carrying either single (S108N), double (C59R + S108N and A16V + S108T), triple (N51I + C59R + S108N and C59R + S108N + I164L) or quadruple (N51I + C59R + S108N + I164L) mutations, responsible for antifolate resistance. The flexibility of the side chain at position N1 has been included in the design so as to avoid

  已开发出一系列灵活的二氨基二氢三嗪或环鸟嘌呤（Cyc）类似物，并显示可抑制野生型的恶性疟原虫二氢叶酸还原酶（PfDHFR）或携带单个（S108N），携带两个（C59R + S108N和A16V + S108T），携带三个（N51I + C59R + S108N和C59R + S108N + I164L）或四倍（N51I + C59R + S108N + I164L）突变，引起抗叶酸耐药性。设计中已包括位置N1的侧链的柔性，以避免与抗性突变体的残基108的侧链发生不利的空间相互作用。许多抑制剂对突变酶的抑制常数在低纳摩尔区域。用A16V和S108N系列突变体都实现了药物结合效率的重新获得。为与突变型酶最佳相互作用而设计的某些酶抑制剂复合物的X射线研究表明，结合模式与Ki值一致。这些化合物中的许多对具有突变酶的抗性恶性疟原虫显示出优异的抗疟活性，并且对哺乳动物细胞显示出低细胞毒性，使其成为抗疟药物的进一步开发的良好候选者。
• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04751302A1

  公开（公告）日：1988-06-14

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR4## in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  化合物的公式（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，且##STR3##可以形成从吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基中选出的饱和杂环环，除吗啡啶基外的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR4##是吗啡啶基；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5位或7位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5位和7位；以及其生理上可接受的酸加成盐。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。